Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

Excellent news folks !!!


In Version 2, Lympro correctly classified AD patients and healthy controls with overall accuracy of 83% while maintaining high degree of sensitivity (90%) and specificity of 71%.

In terms of commercialization of product version 2 seems to be logical choice given sensitivity is 90% means it correctly identifies patients with AD. All big pharma companies want to know if product can diagnose patients correctly that do have AD i.e sensitivity.

In terms of specificity, i.e patients with healthy control groups should be identified as such. We would like to see specificity in the range 85-90% but it is not roadblock to attract big pharma.

Sensitivity is more important than specificity to attract big pharma and data from version 2 suggest high degree of sensitivity (90%) which definitely good sign.

GO AMBS

The Company's initial LP-002 study evaluated 36 patients with moderate-to-severe AD versus a control group of 36 healthy subjects. Data showed that the expression of the marker CD69 on specific subpopulations of lymphocytic cells was statistically significantly lower in the AD groups versus the control group, as measured under two different stimulation conditions (LymPro Version 1 and LymPro Version 2). In Version 1, LymPro correctly classified AD patients and healthy controls with an overall accuracy of 87% (p=0.0015), with a high degree of sensitivity (80%) and specificity (86%). In Version 2, LymPro correctly classified AD patients and healthy controls with an overall accuracy of 83% (p=0.0059) while maintaining a high degree of sensitivity (90%) and specificity (71%). CD69 is a protein expressed when lymphocytic blood cells are in the process of proliferating, and is considered an early marker that cell division is imminent. Low levels of CD69 under cell division conditions in AD patients is suggestive of lymphocytic cell cycle dysregulation and a surrogate marker for the neuronal cell cycle dysregulation that has been observed in the brains of AD patients at autopsy. Cell cycle dysregulation has been identified as a potential link between amyloid beta plaques and tau tangles in AD.

http://ir.stockpr.com/amarantus/company-news/detail/1764/amarantus-completes-enrollment-of-expanded-lp-002-study-of-alzheimers-blood-diagnostic-lympro-testr-to-assess-predictive-value-in-early-stage-disease